AERs Can Prove Causality – FDA Comments On GAO Ephedra Report
This article was originally published in The Tan Sheet
Executive Summary
Statements that adverse event reports are not sufficient on their own to establish causality, "while technically true, are not an adequate reflection of current scientific standards for adverse event assessment," FDA states
You may also be interested in...
FDA Focusing On Ephedra Solution Within DSHEA Parameters, McClellan Says
FDA is committed to operating within the confines of the Dietary Supplement Health & Education Act rather than seeking changes in the law as it prepares for action on ephedra-containing dietary supplements, according to FDA Commissioner Mark McClellan, MD/PhD
FDA Focusing On Ephedra Solution Within DSHEA Parameters, McClellan Says
FDA is committed to operating within the confines of the Dietary Supplement Health & Education Act rather than seeking changes in the law as it prepares for action on ephedra-containing dietary supplements, according to FDA Commissioner Mark McClellan, MD/PhD
FDA Focusing On Ephedra Solution Within DSHEA Parameters, McClellan Says
FDA is committed to operating within the confines of the Dietary Supplement Health & Education Act rather than seeking changes in the law as it prepares for action on ephedra-containing dietary supplements, according to FDA Commissioner Mark McClellan, MD/PhD